Sai Parenterals’ Noumed renews 3-year OTC supply pact in Australia worth AUD 30 mn
Hyderabad, Aug 25 (TNT): Sai Parenterals Ltd on Tuesday said its Australian subsidiary Noumed Pharmaceuticals Pty Ltd has renewed a three-year over-the-counter (OTC) medicines supply agreement with a leading Australian pharmacy chain, valued at AUD 30 million (about ₹204 crore).
The agreement, effective immediately, involves an expanded product portfolio and provides for continued product development and line extensions during the three-year term, the Pharma company said in an investor release.
Under the agreement, Noumed will manage the entire supply chain, including manufacturing, product sourcing, regulatory compliance, TGA registrations, warehousing, quality assurance and nationwide distribution.
Noumed owns the product registrations and marketing authorisations, while the pharmacy chain will retail the products under its own consumer brand, it said.
The renewal takes the value of Noumed’s contracted Australian OTC supply agreements to AUD 232 million (about ₹1,506 crore), including a 7.5-year agreement renewed on July 1, 2026, valued at AUD 202 million.
Sai Parenterals Chairman and Managing Director Anil Kumar Karusala said the two agreements renewed within two months strengthened the company’s long-term contracted OTC business in Australia.
He said products under the agreements were currently largely sourced from third-party manufacturers, with Noumed earning a distribution margin. As the company’s Adelaide facility is commissioned and Indian manufacturing capacity expands, production would progressively move in-house, enabling the same contracted revenue to generate manufacturing margins instead of distribution margins.
Noumed CEO Mark Thulborne said the latest renewal reflected customers’ confidence in the company’s ability to manage the entire supply chain, from sourcing and regulatory compliance to inventory and nationwide distribution.
The agreement would also expand through new product development and line extensions, while local manufacturing at Adelaide was expected to shorten lead times and reduce inventory requirements, he said.
The company said the renewal would strengthen its position in Australia’s regulated OTC market, improve utilisation of its regulatory and manufacturing infrastructure and provide greater visibility of recurring revenues.
Sai Parenterals, an integrated pharmaceutical enterprise, has a portfolio of 302 commercial products across nine therapeutic areas, supported by 599 approved registrations and 67 dossiers under development. Its products are manufactured across six facilities, including five in India and one in Australia.
TNT TS
